The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s showing significant promise in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to provide a more substantial decrease in body size and enhance metabolic markers, p